- HC Wainwright initiated coverage on Tango Therapeutics Inc TNGX with a Buy rating and a price target of $10 per share.
- Tango is a next-generation cancer-focused biotech company primarily focusing on synthetically lethal targets that could address sizable patient populations, including:
- MTAP-null solid tumors with TNG908/TNG462.
- STK11-mutant NSCLC, with TNG260.
- BRCA-mutant solid tumors, with the company's USP1 inhibitor.
- The analyst notes that most pipeline assets are slated to enter the clinic in 2023. TNG908 is being evaluated in a Phase 1/2 trial with three dose expansion cohorts.
- It forecasts that total peak sales of TNG908/TNG462, TNG260, and the company's USP1 inhibitor could reach roughly $5 billion in non-risk adjusted sales by 2030, with the initial launch occurring in the 2026 time frame.
- The company could achieve blockbuster annual sales driven by these compounds as early as 2028. The analyst views the company's agents could be priced in the $14K/month range, in line with the pricing observed for other synthetically lethal agents.
- Price Action: TNGX shares are down 1.15% at $6.90 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in